Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT80 biosimilar to Entyvio in healthy volunteers
NCT06732804Phase 1Completed
- Sponsor
- Alvotech
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of AVT-80 in ulcerative colitis (UC) and Crohn's disease (3 arms), sponsored by Alvotech. Primary endpoint: Pharmacokinetic similarity based on area under the curve. Started Feb 2025; status: completed.
02
Drugs
AVT-80
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT06732804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732804.